Changes in the balance between synaptic glutamate (Glu) release and uptake may stimulate synaptic reorganization and even synapse loss. The search for the primary cause of a potential mismatch between uptake and release should be easier if both parameters are assessed independently and at a single synapse level. This has now become possible due to a new imaging assay with the genetically encoded ultrafast Glu sensor iGlu u . We report results obtained from individual corticostriatal synapses in acute slices prepared from mice aged >1 year. Contrasting patterns of short-term plasticity and a size criterion identified 2 classes of terminals, presumably corresponding to the previously defined IT and PT synapses. The latter exhibited a higher degree of frequency potentiation/residual Glu accumulation and were selected for investigation in the Q175 mouse model of Huntington's disease (HD). It was found that in HD the time constant of perisynaptic [Glu] decay (TauD, as indicator of uptake) and the maximal [Glu] next to the presynaptic terminal (as indicator of release) were prolonged and reduced, respectively. According to these criteria, about 30% of P terminals tested in Q175 heterozygotes (HET) were diagnosed as sick. HD but not WT synapses exhibited a positive correlation between TauD and the peak amplitude of iGlu u . Treatment of WT preparations with the Glu uptake blocker TFB-TBOA (100 nM) mimicked the TauD changes in homozygotes (HOM). The NMDAR-mediated unitary EPSCs elicited by optical activation of single ChR-expressing corticostriatal axons were prolonged, and less EAAT2 immunoreactivity was found in the environment of corticostriatal terminals. It is concluded that HD produces a mismatch between Glu uptake and release, especially in synapses with high degree of frequency potentiation. Astrocytic Glu transport therefore remains a promising target for therapeutic intervention.
INTRODUCTION
A low level of steady state glutamate concentration [Glu] is an important prerequisite for high spatial and temporal discrimination of afferent signals. Electrogenic transport of Glu from the environment of active synaptic terminals into astroglial cells secures resting [Glu] levels below 100 nm (Bergles et al., 1999; Marcaggi and Attwell, 2004; Tzingounis and Wadiche, 2007; Nedergaard and Verkhratsky, 2012; Papouin et al., 2017; Rose et al., 2018) . Compared to other synaptically enriched proteins, including the AMPA receptors, excitatory amino acid transport proteins (EAAT1 and EAAT2, GLAST and GLT1 in rodents) are very abundant (Lehre and Danbolt, 1998; Marcaggi and Attwell, 2004; Cahoy et al., 2008) forming clusters on the perisynaptic astroglial processes (PAPs) next to the sites of transmitter release (Lehre and Danbolt, 1998; Melone et al., 2011) . However, the proximity between the sites of synaptic Glu release and astrocytic uptake could vary according to the type of synapse or the functional state of the involved cells (Octeau et al., 2018) .
Insufficient expression/activity of EAAT2 is considered among the mechanisms promoting excitotoxic damage and neurodegeneration (Pekny et al., 2016; Verkhratsky et al., 2016) . As for HD, there is full agreement that transcription of the EAAT2 encoding gene SLC1A2 and tissue uptake of radio-labelled EAAT2 substrates are reduced in comparison with healthy controls (Lievens et al., 2001; Behrens et al., 2002; Shin et al., 2005; Miller et al., 2008; Bradford et al., 2009; Faideau et al., 2010; Huang et al., 2010; Menalled et al., 2012; Grewer et al., 2014; Meunier et al., 2016) . Records from striatal astrocytes (Dvorzhak et al., 2016) suggested a 20-30% decrease of the glutamate uptake activity in two mouse models of HD, R6/2 and Q175. Yet some caution is needed as it has remained unclear whether or not the well-documented reduction of astrocytic Glu transport is to be regarded as a primary cause of synapse dysfunction or loss, or merely represents an epiphenomenon reflecting glial adjustment to the massive pruning of glutamatergic terminals for other yet unknown reasons (Deng et al., 2013; Rothe et al., 2015) . As synapse degeneration is likely to progress in a rather asynchronous manner resulting in a co-existence of sick and more or less healthy terminals, a satisfying answer to the question of functional adequacy of astrocytic glutamate uptake in HD can only be obtained at the single synapse level and under consideration of the individual uptake/release relationships (Barbour, 2001; Nahir and Jahr, 2013; Jensen et al., 2017; Reynolds et al., 2018) .
The striatum as the most affected brain structure in HD (Khakh et al., 2017) is well suited for selective activation of glutamatergic synapses as it lacks intrinsic glutamatergic neurons. Glutamatergic afferents originate in the medial thalamus and the cerebral cortex (see (Reiner and Deng, 2018) for more). Corticostriatal connections are formed by at least two distinct populations of pyramidal neurons, localized in layers 2/3 and 5. The axons originating in layer 2/3 establish bilateral intra-telencephalic (IT) connections, while layer 5 axons enter the pyramidal tract (PT) and lack telencephalic collaterals to the contralateral side. Elegant electrophysiology (Kincaid et al., 1998) and electron microscopy studies (Reiner et al., 2010) discovered a number of differences between PT and IT afferents and their synaptic varicosities. In view of this diversity one could expect some type-dependent differences in the release characteristics and, accordingly, differential sensitivity to factors that may cause an uptake/release imbalance.
Here we report the results of the first single synapse experiments in striatal slices of adult mice performed with the ultrafast Glu sensor iGlu u (Helassa et al., 2018) . We have addressed three main questions: 1) How does activation frequency affect the Glu release and uptake at corticostriatal terminals? 2) Does HD produce an uptake/release mismatch? 3) If so, would this mismatch be based on uptake insufficiency rather than excessive release?
MATERIALS AND METHODS Animals. The work described here has been carried out in accordance with the EU Directive 2010/63/EU for animal experiments and was registered at the Berlin Office of Health Protection and Technical Safety (G0233/14 and G0218/17). Z-Q175-KI mice were obtained from CHDI ("Cure Huntington's Disease Initiative", see stock # 027410 of the Jackson Laboratory). The number of CAG repeats ranged from 122 to 193. The recordings were performed at an age of 51 to 76 weeks.
Plasmids. pAAV-CaMKIIa-ChR2(H134R)-EYFP and pAAV-CaMKIIa-hChR2(E123T/T159C)-EYFP (Addgene #26969 and #35511) were gifts from Karl Deisseroth. To create pAAV-CaMKIIa-iGlu u (Addgene #75443), the iGlu u gene was amplified by PCR from pCI-syn-iGlu u (Addgene #106122) using Phusion polymerase (forward 5'-CATCAGGATCCATGGAGACAGACACACTCC-3', reverse 5'-GTATGGAATTCCTAACGTGGCTTCTTCTGCC-3') and cloned into pAAV-CaMKIIa-hChR2(H134R)-EYFP by restriction-ligation using BamHI/EcoRI restriction enzymes (NEB) and T4 DNA ligase (NEB). AAV9-CaMKIIa.iGlu u .WPRE-hGH and AAV9-CaMKIIa.hChR2(E123T/T159C)-EYFP.hGH were packaged at University of Pennsylvania Vector Core (Penn Vector Core).
Drugs and antibodies. All the substances were obtained from Sigma Aldrich, except TTX (Abcam), CEF and TFB-TBOA (both Tocris). The primary antibodies included those to vGluT1 (1:1000, guinea pig, Synaptic Systems #135304) and EAAT2 (1:2000, rabbit, Abcam #ab41621). Secondary antibodies against guinea pig and rabbit, were conjugated to Alexa 488 or 555 and obtained from Life Technologies (#A-11073, #A-21429, respectively).
Injections and brain slice preparation. The animals were anesthetized by intraperitoneal injection of a mixture containing 87.5 mg/kg ketamine and 12.5 mg/kg xylasine before receiving 4 intracortical injections of AAV9-CamKII.iGlu u .WPRE-hGH (7.34*10 13 gcC/ml -0.3 µl) or 1 intracortical injection of AAV9-CaMKIIa.hChR2(E123T/T159C)-EYFP.hGH (6.28*10 12 gc/ml -1 µl) at the following coordinates with respect to bregma (mm): anterior 1.5, lateral 1.56, 1.8, 2.04, 2.28 and ventral 1.7. About 3 weeks (ChR2) or 6 weeks (iGlu u ) later the animals were anesthetized with isoflurane, transcardially perfused with cooled aerated saline containing (in mM): N-methylglucamine chloride (NMDG) 92, KCl 2.5, NaH 2 PO 4 1.25, NaHCO 3 25, glucose 20, CaCl 2 0.5, MgCl 2 10, sodium pyruvate 3, and sodium ascorbate 5 (pH 7.35, 303 mosmol/l). After decapitation and removals of the brains, parasagittal (10 deg off) sections (300 µm) containing the striatum were prepared as previously described (Dvorzhak et al., 2016) . The slices were kept in artificial cerebrospinal fluid (ACSF) containing (in mM): NaCl 125, KCl 3, NaH 2 PO 4 1.25, NaHCO 3 25, CaCl 2 2, MgCl 2 1, glucose 10 (pH 7.3, 303 mosmol/l), supplemented with (in mM): sodium pyruvate 0.5, sodium ascorbate 2.8 and glutathione 0.005. These perfusion and recovery solutions preserved the astrocytes better than physiological ACSF, sucrose-or choline-containing solutions, the criteria being resting membrane potential at break-in (WT: <=-85 mV). Ten Q175 HOM were also injected with CEF (5 consecutive days before testing, 200 mg/kg i.p.) or the respective control solution (physiological saline). [Glu] elevations with iGlu u . The biophysical characteristics of the new ultrafast Glu sensor (iGlu u ) were already described (Helassa et al., 2018) . Briefly, at 20 o C the responses of transduced HEK293T cells to saturating Glu concentration (10 mM) decayed with a time constant of 2.1 ms. For the imaging of synaptically released Glu, slices were submerged into a perfusion chamber with a constant flow of oxygenated ACSF at a rate of 1-2 ml/min. Temperature during the recordings was maintained at 26 -27 °C. In nonstimulated acute slices from >1 year old mice corticostriatal varicosities were visualized in the dorsal striatum using a Zeiss W Plan-Apochromat 63x /NA 1.0 water immersion objective and brief (180 ms) discontinuous exposure to a 473 nm laser beam focused to a circular area of ~4.5 µm in diameter centered to a presynaptic varicosity. The distance to the nearest other fluorescent varicosity was typically 3 to 5 µm. The size of non-stimulated boutons was derived from the area of supra-threshold pixels, the threshold being defined as mean ROI intensity + 3 SD. For evaluation of evoked responses, the iGlu u fluorescence was acquired at a frequency of 2.5 kHz from a rectangular ROI of 4 µm x 4 µm (20 x 20 pixels, binning 2) using a sCMOS camera (Andor Zyla4.2 plus) attached to a Zeiss wide field microscope (AxioObserver). In-house written software routines controlled the laser, camera and electrical stimulation of the axon/bouton. Each pixel of the ROI was evaluated separately for the construction of time-and space-dependent [Glu] profiles after release. The iGlu u intensity values were expressed as supra-threshold pixel fluorescence F in % of the mean baseline fluorescence derived from the data points acquired during a 50 ms period prior to stimulation.
Quantification of perisynaptic
For the description of the stimulus-induced changes of iGlu u we defined the following parameters. The term "peak amplitude" or "mean F/F at peak" refers to the time-dependent changes ("transients") of mean F/F values, as calculated from all supra-threshold pixels (see Fig. 1E for a specimen). The term "maximal amplitude" (see Fig. 5A -C) refers to the timedependent changes ("transients") of the pixel with the highest elevation of iGlu u fluorescence after single pulse activation. Typically this would be a pixel in close proximity with the bouton borders delineated at rest. Accordingly, the TauD values either refer to the decay from peak or maximal amplitudes. If not mentioned otherwise, TauD is obtained by fitting a monoexponential function to the decay of individual evoked transients. "Residual F/F" is derived from fitting a double exponential function to the decay of mean supra-threshold pixel values after the last stimulus. It roughly corresponds to the F/F value at the intercept between the fast and slow phase of iGlu u decay (see Fig. 2H ). "Integral F/F" is the sum of all F/F values during a period of 70 ms starting with the first stimulus (see Fig. 2I ). The spatial extension of the iGlu u signal ("Spread") is defined as the diameter of the area of all suprathreshold pixels combined to form virtual circle.
Single axon/bouton activation. To induce the Glu release from individual synaptic boutons under physiological conditions, a depolarizing current pulse was applied through an ACSFfilled glass pipette (tip diameter <1 µM, resistance 10 MOhm) placed next to an axon in close proximity with a fluorescent varicosity. Responses were elicited at minimal intensity at a repetition frequency of 0.1 Hz. They disappeared when the pipette was moved by as little as 5 pixel diameters (1 µm). Single bouton recording of iGlu u in the presence of TTX was performed in elevated (5 mM) [Ca 2+ ] ec using a biphasic stimulation. For more details on single bouton activation and recording of unitary EPSCs see (Kirischuk et al., 1999; Kirischuk et al., 2002) and (Dvorzhak et al., 2013a) . (uEPSCs) . uEPSCs were recorded in the presence of bicuculline methiodide (BMI) as previously described (Dvorzhak et al., 2013b) . Briefly, the intra-pipette solution contained (in mM): cesium methane sulfonate 100, CsCl 50, NaCl 5, CaCl 2 0.5, EGTA 2.5, Hepes 25, MgATP 2, GTP 0.3 (pH 7.2). uEPSC were induced via optical activation of APs in hChR2(E123T/T159C)-EYFP expressing corticostriatal axons. Using the point illumination system UGA-42 of Rapp OptoElectronic, the duration and size of the laser pulse was adjusted to activate a synaptic response with distinct threshold. Stimulation was accepted as minimal if the following criteria were satisfied: (i) uEPSC latency remained stable (fluctuations <20% of means, (ii) lowering stimulus duration by 20% resulted in a complete failure of uEPSCs, (iii) an increase in stimulus duration by 20% neither changed mean amplitude nor shape of uEPSCs. To elicit AMPAR-and NMDAR-mediated components of uEPSCs, records were performed at holding potentials of −70 mV and +50 mV, respectively. Synaptic EAAT2 immunofluorescence. Using deep isoflurane anesthesia, mice were transcardially perfused with ice-cold phosphate-buffered saline (PBS) followed by a solution of 4% (w/v) paraformaldehyde in PBS. Sagittal sections (30 µm) were prepared as previously described (Rothe et al., 2015) . Freely floating sections were double-stained with guinea pig anti-vGluT1 (1:1000) and rabbit anti EAAT2 (1:2000), followed by respective secondary antibodies at a concentration of 1:800. Images were acquired using a Zeiss 100x oil immersion objective (NA1.3). ROIs of 30 x 30 pixels (pixel size 0.074 µm) were centred to a single vGluT1 spot and the supra-threshold (Th = mean + 2.5 SD) EAAT2-positive pixels were determined for estimation of the mean the immunofluorescence (IF) intensity and area of the EAAT2+ spots. Evaluation was performed using Autoquant X3 (MediaCybernetics) for deconvolution of the vGluT1 images. The respective EAAT2 images were evaluated based on the original images using the Nemo 1.43 software routine of C. Henneberger. The sections from 4 WT and 4 Q175 HOM were stained together, and all images were acquired with the same camera settings (Spot Insight, Diagnostic Instruments).
Patch-clamp recording of unitary EPSCs
Statistics. Data is presented as means ± s.e.m. and was analyzed by paired and unpaired t-test or the nonparametric Mann-Whitney test, one-way or two-way ANOVA or the respective non-parametric Kruskal-Wallis test with posthoc comparison of individual means, as indicated. P values of <0.05 was considered statistically significant. Significance levels were marked by asterisks, where * corresponds to P<0.05, ** -P<0.01 and *** -P<0.001. The numbers indicate animals, cells or presynaptic terminals, as indicated in the figure legends or tables. HD-related differences are described in % of WT levels, %WT (Tabs. 2, 3).
RESULTS
Evaluation of action potential-(AP-)mediated perisynaptic corticostriatal Glu transients using the new ultrafast sensor iGlu u in acute slices from adult mice Placement of stimulating electrodes in the vicinity of corticostriatal terminals at rest was carried out under visual guidance ( Fig. 1A) . Bouton size was defined on the basis of resting fluorescence in the region of interest, ROI ( Fig. 1 , area boxed in blue). The deduced virtual diameter exhibited a bimodal distribution (Fig. 1C ). Varicosities with a diameter <=0.57 µm were defined as "Small" and, for the sake of brevity, tentatively referred to as IT type. Accordingly, varicosities with d >=0.63 µm were classified as "Large" or PT type.
After electrical stimulation of a fluorescent corticostriatal axon in the dorsal striatum iGlu u intensity increased in the pixels adjacent to the area defined as resting terminal (Fig. 1D ). Mean supra-threshold pixel intensity F/F was plotted against time ( Fig. 1E , middle trace), and a monoexponential function was fitted to the stimulus-induced iGlu u transient F/F to determine TauD. In the case of single pulse activation, there was no significant correlation between TauD and bouton diameter (not illustrated).
The focus of the current experiments was placed on the time course of the iGlu u signals. The position of the sensor and its low affinity for Glu naturally set limits to the detection of [Glu] elevations at larger distance from the site of vesicle exocytosis. Nevertheless, we also expected some preliminary information on the spatial characteristics of the iGlu u signal. Therefore, a virtual diameter ("Spread") was deduced from the projection of the suprathreshold iGlu u signal to the focal plane and plotted against time ( Fig. 1E , lower trace). Under condition of single pulse activation "Spread" exhibited a significant positive correlation with TauD ( Fig. 1F ), but the mean values of maximal amplitude, peak amplitude, TauD and Spread were not different between the two types of terminals after single pulse activation (Tab. 1, Fig. 1G ).
The differences between I-and P-type terminals became more obvious with repetitive stimulation. Activation with stimulus pairs at an interval of 50 ms revealed differences in the paired pulse ratios (PPR) of peak amplitudes resulting in a positive correlation between PPR and bouton diameter (Fig. 1H ). This finding validated our size criterion for terminal separation and provided a first hint that IT and PT terminals may generate a differential load for Glu clearance when repeatedly activated.
Frequency-dependent potentiation of Glu release at PT but not IT corticostriatal terminals As we aimed at exploring the limits of Glu release under conditions resembling the cortical activity during movement initiation, we applied 2, 3 and 6 stimuli at frequencies of 20, 40 and 100 Hz to elicit AP-mediated Glu release. At all frequencies tested, Small/IT and Large/PT terminals exhibited opposite types of short-term plasticity, i.e. depression in IT and potentiation in PT terminals (Tab. 1 and Fig. 2A-E ). In general, the peak and maximal amplitudes observed after stimulus #6 (normalized to response #1) were higher after 100 vs. 20 Hz, and larger in PT than IT terminals (Tab. 1, Fig. 2E ). The TauD values, as derived from the first term of a double exponential fitting curve after stimulus #6 (double arrow in Fig. 2D ), exhibited little sensitivity to repetitive activation up to 100 Hz, (Fig. 2F ), but the Spread of the iGlu u signals increased with repetitive stimulation at 100 Hz, notably at PT terminals ( Fig.  2G ). PT terminals also accumulated larger amounts of residual iGlu u fluorescence ( Fig. 2H ), as defined by fitting a double exponential function to the #6 decay (Fig. 2D ). The data suggests that the stimulus-locked response to the last AP adds to incompletely cleared Glu. Accordingly, the integral iGlu u fluorescence produced by 6 pulses at 100 Hz was significantly larger in PT terminals ( Fig. 2I ). Thus, under repetitive activation conditions, large PT corticostriatal terminals might be more affected by conditions of weak astrocytic Glu uptake.
Directly induced Glu transients in tetrodotoxin (TTX) With the AP mechanism intact, fluorescence might also originate from neighbouring release sites, especially if the axon heads deeper into the z-plane of the slice. In case of the serial (en passant) type synapses (as characteristic of PT afferents) this could erroneously increase signal duration and spread. Another caveat to be faced in the case of HD preparations is a possible alteration of voltage-activated channels in the cortical afferents (Silva et al., 2017) which may affect the duration of the presynaptic depolarization, the influx of Ca 2+ and, consequently, the amplitude and duration of iGlu u signals, without having a direct impact on the clearance machinery of the astrocytes. Moreover, respective deficits might preferentially occur in IT or PT axons. Considering these complexities it was decided to by-pass the AP mechanism by directly depolarizing the glutamatergic terminals in TTX and to perform the following measurements solely in PT synapses.
To achieve in TTX [Glu] elevations similar to those obtained under physiological activation conditions from PT terminals at 100 Hz, it was sufficient to increase [Ca 2+ ] ec to 5 mM and to add a hyperpolarizing prepulse to the standard 1 ms depolarization used both in AP and TTX experiments. In the absence of a conditioning hyperpolarizing prepulse, the direct depolarization was insufficient to elicit release (Fig. 3A) . The results of Fig. 3B -D indicate that the selected protocol provided a good match between the physiologically induced #6 responses at 100 Hz and the directly induced responses in TTX. In any case, iGlu u elevations were completely abolished by the Ca 2+ channel blocker Cd 2+ (Fig. 3E ). This stimulation protocol was then expected to provide a reasonably standardized single terminal activation for assessing the Glu uptake of WT vs. HD mice.
Slowed Glu clearance at single PT-type corticostriatal terminals in HD In the Q175 mouse model of HD, motor symptoms (hypo-and dyskinesia, pathological circling) develop quite slowly. However, at the age of one year and older, both Q175 HET and HOM resemble the human phenotype in the manifest phase (Khakh et al., 2017) . In Q175 HOM motor impairment coincided with the appearance of pathological gamma oscillations in the local field potential (LFP) recordings at quiet rest (Rothe et al., 2015) . In R6/2 mice, the changes in the LFP power spectrum were less pronounced after treatment with ceftriaxone (CEF), a transcriptional activator reported to increase the level of EAAT2 protein in the dorsal striatum . Fig. 4A shows representative amplitude-scaled specimen records for the three test groups illustrating our main finding: In HD slices the iGlu u transients decayed more slowly (link to video: https://neurophysiology-grantyn.charite.de/video/Q175_iGluSnFr-ultrafast_WT_HET_HOM_2fps.ogg ). Interestingly, this HD-related alteration was not only present in Q175 HOM but also in HET (Fig. 4B ) thereby underlining the usefulness of the Q175 mouse model for research on HD pathology and therapy.
An important additional question concerns the amount of released Glu. Is it larger in HD mice? This was not the case, on the contrary. With respect to WT, Q175 HET and HOM exhibited a significant deficit in the peak F/F values (Tab. 2, Fig. 4C ). This result is in line with the data from R6/2 (Parievsky et al., 2017) suggesting that the presently disclosed HDrelated prolongation of the iGlu u signal occurs despite a concomitant decrease in the Glu output from single PT terminals.
Nevertheless, the above observations do not immediately prove that the prolongation of the F/F transient is due to an altered functionality of the astrocytes. It was at least necessary to clarify whether TauD values responded to pharmacological manipulation of astrocytic Glu transport. This was the case. The iGlu u transients of PT terminals exhibited a clear sensitivity to TFB-TBOA (Fig. 4D) . In WT, 100 nM of the antagonist prolonged the iGlu u decay to the same extent as the disease, the effect of pharmacological EAAT2 block being less pronounced in Q175 HOM (Fig. 4E, F) .
Although iGlu u expression in the presynaptic terminals cannot provide exhausting information on the spatial characteristics of perisynaptic [Glu] , it should be noted that the "Spread" (black outlines in Fig. 4G ) was also increased, reaching 1.61± 0.14 µm (n=19) in HOM (Tab. 2). According to the presently available models of glutamatergic synapses (Zheng et al., 2008; Scimemi and Beato, 2009 ), this should be sufficient to activate extrasynaptic NMDA receptors.
The pixels with the highest F/F were always located next to the outline of the resting terminal (see Fig. 1D ). The decay from the maximal amplitude next to the active zone thereby was used to estimate clearance at the site of release minimizing the influence of Glu diffusion. The graphs of Fig. 5A -C show the ranges of maximal amplitudes and TauD and reveal the synaptic symptoms of HD on first glance: i.e. a decrease in the range of maximal amplitudes next to the source of Glu elevation and an increase in the range of TauD. As a first approximation, one can state that in Q175 HET 30% of the synapses (19/68) were sick, the present exclusion criterion from the group of healthy synapses being TauD >= 10 ms and/or maximal F/F <200%.
Positive correlation between Glu release and clearance in HD but not WT synapses
In the case that the density of astrocytic Glu transporters next to the site of release is compromised by HD, more distantly located transporters could come into play which might be reflected by a positive correlation between TauD and peak amplitudes derived from fluctuating responses generated by a given synapse. To eliminate the impact of inter-synapse variability in favour of an analysis of inter-trial variability we plotted the respective PPR values, i.e. examined the normalized 2 nd responses ( Fig. 5D-F) . This approached revealed that in HD but not WT synapses larger [Glu] elevations indeed required longer time for clearance which suggests that in HD Glu may find its astrocytic transporter at bigger distance, in line with recent FRET data from corticostriatal synapses in R6/2 (Octeau et al., 2018) .
Prolonged NMDAR components of unitary EPSCs in HD NMDARs are sensitive indicators of [Glu] and therefore well suited to detect a potentially existing Glu clearance deficiency in the environment of active synapses, provided that the analysed responses are derived from one or few synapses only (Chiu and Jahr, 2017) . Here we used focal optical activation of individual corticostriatal axons to record uEPSCs at -70 and +50 mV. The experiments showed (Tab. 3) that the T50 value of the uEPSC recorded at +50 mV is i) solely dependent on NMDARs, ii) prolonged in Q175 HD and iii) recovered to WT levels after treatment with CEF suggesting a sensitivity of corticostriatal input to the level of EAAT2 expression (Tab. 3, Fig. 6A-F) . There also was an increase in the peak amplitudes of the uEPSCs recorded both at +50 mV and -70 mV which may, at least in part, reflect reduced lower failure rate due to more efficient ChR-mediated depolarization of the stimulated axons. In accordance with this idea, not only the failure rate but also the coefficient of variation (CV) of the AMPA response at -70 was found to be smaller in HD (Fig. 6E, F) . In any case, these results are in line with the concept that HD slows glutamate clearance.
Reduced perisynaptic EAAT2 protein at corticostriatal terminals To clarify whether the observed clearance deficit is indeed accompanied by a reduction of EAAT2 protein levels in the environment of corticostriatal terminals, we performed a quantification of EAAT2 IF in small ROIs centred to single vGluT1-positive terminals of fixed sections (Fig. 7A-E) . These experiments revealed a small (-15%) but significant HDdependent decrease in the mean intensity of supra-threshold EAAT2+ pixels, along with a significant (-13%) decrease in the size of the EAAT+ area.
DISCUSSION
The analysis of single synapse iGlu u transients in acute slice preparations from adult mice provides new information on Glu clearance in its relation to the respective transmitter load. To summarize: 1) The peak [Glu] elevations produced by PT and IT terminals differed significantly (factor 5:1). 2) However, throughout the Glu challenges tested in normal mice, both types of synapses coped with the induced [Glu] elevations (did not show much increase of TauD even at 100 Hz activation), although the Spread and the residual iGlu u fluorescence increased with increasing peak amplitudes, notably at PT terminals. 3) HD decreased the range of maximal amplitudes but increased the range of TauD. About one third of the synapses tested in Q175 HET were diagnosed with a functional defect, based on the time needed for Glu clearance (Tau D of iGlu u >= 10 ms) and/or the amount of released Glu (maximal F/F <= 200%). 4) The responses to paired (t=50 ms) activation at 0.1 Hz exhibited some inter-trial variabilty of the #2 responses. This analysis revealed a diseaserelated loss of independence between the indicators of uptake on release. In Q175 HET but not WT, larger individual responses were associated with larger TauD. 5) The NMDARmediated unitary EPSCs elicited by optical stimulation of single ChR-expressing corticostriatal axons were prolonged in Q175 HOM. 5) Also in Q175 HOM, less EAAT2 was found in the environment of corticostriatal terminals.
PT versus IT terminals
The unexpected differences in the properties of PT vs. IT terminals raise further questions on the mechanism(s) of release plasticity of the glutamatergic afferents to the dorsal striatum. Previous electrophysiological studies (Ding et al., 2008) implied that corticostriatal connections preferentially exhibit paired pulse facilitation (PPF) while thalamostriatal connections are prone to paired pulse depression (PPD). Our results confirm preferential PPF with regard to the PT subgroup of corticostriatal afferents under physiological activation conditions (Tab. 1). However, as in any other synapse (for instance (Kirischuk et al., 2002) ), a conversion from PPF to PPD is easily achieved by increasing the Ca 2+ influx. There is a widely accepted rule of thumb suggesting that smaller initial responses are likely to produce facilitation in subsequent responses, and vice versa. Considering that under the same experimental conditions PT and IT terminals produced about the same initial Glu output, but opposite types of plasticity, one can assume that these terminals indeed represent two classes of afferents with some differences in the presynaptic control of transmitter release.
Under condition of repetitive activation the size of synaptic terminals and associated differences in the vesicle pool size could affect the integral Glu output, but also the degree of Glu escape (Genoud et al., 2006; Bernardinelli et al., 2014; Medvedev et al., 2014; Gavrilov et al., 2018) . It has been hypothesized that thicker terminals could push the PAPs further away from the site of exocytosis which may result in wider signal spread if the transporters are challenged with a pronounced build-up of [Glu] as found in PT terminals.
The hypothesis of non-saturating Glu uptake in healthy glutamatergic synapses In view of a long history of changing opinions on the significance of astrocytic Glu transport as a possible determinant of synaptic strength it is good to have new tools at hand to shed light on the possible limits of Glu clearance in health and disease. Our uEPSC data from synaptic connections with one or few terminals confirm the long-standing idea that a weakness of Glu uptake has little influence on the decay kinetics of the fast desensitizing AMPA responses (Hestrin et al., 1990; Asztely et al., 1997; Goubard et al., 2011; Campbell et al., 2014) . Moreover, our iGlu u data from healthy mice are in line with the more controversial prediction that in "normal" glutamatergic synapses glutamate transport would cope with any amount of physiologically released Glu (Diamond and Jahr, 2000; Tzingounis and Wadiche, 2007) . Nevertheless, the present iGlu u -based postulate of non-saturating Glu uptake for ITand PT-type corticostriatal synapses will need further verification under a wider range of conditions. It was already shown that the state of astrocytes could affect the structural plasticity of PAPs (Theodosis et al., 2008; Reichenbach et al., 2010; Bernardinelli et al., 2014; Heller and Rusakov, 2015; Verkhratsky and Nedergaard, 2018) . Activity-and diseasedependent PAP retraction could then produce a large variety of spill-out and spill-in effects which may not only change the access of the available transmitter(s) to respective neuronal and glial receptors, but also influence the efficacy of the astrocytic transport machinery itself (Armbruster et al., 2016) .
Evidence for impairment of Glu clearance in HD Symptomatic HD is characterized by the loss of glutamatergic terminals in the dorsal striatum but it is still not clear whether this disease-related process of synapse pruning is to be attributed to glutamate excitotoxicity (Reiner and Deng, 2018) . While the long-term consequences of reduced Glu clearance remain to be clarified, our present experiments provide new evidence suggesting that in symptomatic Q175 mice a significant fraction of PT synapses is afflicted by the disease, most likely exhibiting alterations in both uptake and release. When normalizing the fluctuating iGlu u amplitudes generated in the course of repeated activation of the same synapse, it turned out that HD but not WT synapses displayed a positive, presumably pathological correlation between TauD and maximal F/F amplitudes. In view of the observed TBOA effects and the decrease of perisynaptic EAAT2 protein, it seems very likely that the observed synapse pathology is associated with the expression of mHTT in astrocytes (Faideau et al., 2010) .
How do the present results obtained with iGlu u in the HD striatum relate to synaptic properties outlined by more conventional electrophysiological approaches? The results on iGlu u Spread are in line with the prolonged NMDAR activation revealed in the uEPSCs experiments of Q175 HOM. However, the slight but significant increase of uEPSC amplitudes will need a verification with other single axon stimulation techniques. Previous experiments with minimal electrical stimulation (Rothe et al., 2015) pointed to a decreased range of uEPSC amplitudes, as expected in the case of reduced number of Glu-releasing sites or smaller vesicle pools.
Considering the novelty of the present approach, it is not surprising that some results from other labs were not confirmed, in particular those obtained with the slow Glu indicator iGluSNFR (Marvin et al., 2013) . (Parsons et al., 2016) activated glutamate release by high frequency electrical field stimulation and used the iGluSnFR sensor to record Glu elevations in large viewfields. They found no HD-related difference in the fluorescence decay, in contrast to (Jiang et al., 2016) . Both studies were carried out in R6/2 mice, the main difference being in the expression of the Glu sensor in neurons vs. astrocytes. (Parievsky et al., 2017) applied optical field stimulation of channel-rhodopsin-(ChR2(H134R))-expressing corticostriatal axons to induce EPSCs in SPNs.. This approach showed no increase in the decay times (T90-10) of NMDAR-mediated currents. On the contrary, the latter were significantly shorter in HD. However, considering the mean T90-10 values of this study (~750 ms) it seems possible that the asynchrony of release characteristic of this type of optical field stimulation may not give the resolution needed for the estimation of synaptic Glu clearance. In general, space-and volume-averaging effects resulting from bulk activation of synaptic and non-synaptic Glu release and low resolution of the electrical or fluorescent signals can be expected to influence the interpretation of results on Glu uptake and release (see (Jensen et al., 2017; Reynolds et al., 2018) for a concise summary on these issues).
The ultimate prove of Glu uptake deficiency as a cause of synapse pathology in the dorsal striatum will be the recovery of normal synaptic performance after a therapeutic intervention targeting the astrocytes. Functional benefits from CEF injections have already been reported (Miller et al., 2008; Miller et al., 2012) and were attributed to a enhanced EAAT2 expression in astroglia. Attempts to achieve beneficial effects by injecting recombinant astrocytetargeting AAV8-EAAT2 constructs failed in a SOD1 mouse model of amyotrophic lateral sclerosis (Li et al., 2015) but were successful in reversing established neuropathic pain behavior (Falnikar et al., 2016) . Most intriguing, intrastriatal injection of a recombinant viral Kir4.1 vector restored a normal level of EAAT2 protein (Tong et al., 2014) . However, it is not yet clear whether a mere stimulation of EAAT2 expression would suffice to achieve the desired reversal of motor symptoms in HD, because synaptic targeting and the activity of Glu transporters are also influenced by local translation (Sakers et al., 2017) , lateral mobility (Murphy-Royal et al., 2015) and internalization (Leinenweber et al., 2011; Ibanez et al., 2016) . Clearly, much more information is needed to understand the regulation of Glu uptake in the context of other astrocytic signaling cascades.
Conclusion
Achievement of normal EAAT2 function should remain a major goal in the therapy of HD. (Reiner et al., 2010) , illustrating the concept of preferential projection of pyramidal tract (PT) neurons to indirect pathway striatal projection neurons (iSPNs) and intratelencephalic (IT) neurons to direct pathway SPNs (dSPNs) and size-differences between the IT and PT terminals. Bimodal distribution of bouton diameters as determined by the supra-threshold resting fluorescence before stimulation. Boutons with diameter >= 0.63 µm were defined as "Large" and assumed to be issued by PT axons. (D) Example of a type PT bouton with the respective iGlu u fluorescence at rest (left) and at the peak of an AP-mediated iGlu u response (right). (E) iGlu u responses recorded from the bouton shown in (A, D) . Experiment in 2 mM Ca 2+ and 1 mM Mg 2+ . Simultaneous recording of stimulation current (upper trace), mean supra-threshold pixel intensity (middle trace) and the area of supra-threshold pixels (bottom trace). A monoexponential function is fitted to the decay of the 1 st (#1) iGlu u transient with the respective time constants shown next to the fitting curves. (F) Positive correlation between the "Spread" at the time of peak and TauD after stimulus #1. (G) Peak amplitudes of responses to stimulus #1. There is no difference between small and large terminals. (H) Significant correlation between the PPR of peak amplitudes and bouton diameter for single or #1 stimuli. HET (B, C) . To emphasize the HD-related differences in the range of obtained values, the data points were boxed green in WT and red in Q175 HET. (D-F) Correlograms of TauD and peak amplitudes of F/F. To eliminate intersynapse variability, #2 responses were normalized to #1 responses. The inter-trial variability of responses elicited at a repetition frequency of 0.1 Hz was used to test for a positive correlation between TauD and peak amplitudes of F/F. Note positive correlation in HET (F) but not WT (D, E). Data from HET: 11 animals, 23 synapses, 3 trials per synapse. 
